(Q51023376)

27 March 2018

title

A selective ALK inhibitor in ALK-rearranged patients. (English)

1 reference

27 March 2018

author

James Chih-Hsin Yang

series ordinal

1

1 reference

27 March 2018

publication date

30 April 2013

1 reference

27 March 2018

Lancet Oncology Commission

published in

1 reference

27 March 2018

volume

14

1 reference

27 March 2018

issue

7

1 reference

27 March 2018

page(s)

564-565

1 reference

27 March 2018

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

ALK in lung cancer: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970170-0

7 January 2021

10.1016/S1470-2045(13)70170-0

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

23639469

1 reference

27 March 2018